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In the proximal tubule, angiotensin II (Ang-II) regulates HCO3
reabsorption and Hþ secretion by binding the type 1 Ang-II
(AT1) receptor, stimulating Naþ /HCO3 cotransport and Na
þ /
Hþ exchange. Studies were carried out to determine if long-
term changes in Ang-II receptor occupation alter the
abundance of the basolateral Naþ /HCO3 cotransporter
(NBC1) or the apical membrane type 3 Naþ /Hþ exchanger
(NHE3). In the first set of experiments, rats eating a low-
sodium diet were infused with the AT1 blocker, candesartan,
or vehicle. In the second, lisinopril-infused rats were infused
with either Ang II or vehicle. Transporter abundances were
determined in whole kidney homogenates (WKH) and in
brush border membrane (BBM) preparations by
semiquantitative immunoblotting. Tissue distribution of
transporters was assessed by immunocytochemistry.
Blockade of the AT1 receptor by candesartan caused
decreased abundance of NBC1 in WKH (5979% of control;
Po0.05) and Ang-II infusion increased abundance (13077%
of control; Po0.05). Changes in NBC1 in response to
candesartan were confirmed immunohistochemically. Neither
candesartan nor Ang II infusion affected the abundance of
NHE3 in WKH or cortical homogenates. Candesartan
decreased type 2 sodium-phosphate cotransporter
abundance in both WKH (5277% of control; Po0.05) and
BBM (3277% of control; Po0.05). Serum bicarbonate was
decreased by candesartan and increased by Ang-II.
Candesartan also decreased urinary ammonium excretion
(Po0.05). The long-term effects of Ang-II in the proximal
tubule may be mediated in part by regulation of NBC1
abundance, modifying bicarbonate reabsorption.
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Angiotensin II (Ang-II) regulates acid–base transport in the
proximal tubule by stimulating active apical Hþ secretion,
apical Na7Hþ exchange,1–3 and basolateral Naþ /HCO3
cotransport4 as well as by enhancing ammonium secretion5
in response to acid loading. In addition, Ang-II helps to
maintain sodium balance during periods of dietary sodium
restriction or contraction of extracellular fluid volume6 by
increasing fluid and NaCl reabsorption in the proximal
tubule.7,8 Ang-II produces its effects, at least in part, due to
direct action in the renal tubule.9 Those effects are mediated
by binding to the type 1 Ang-II (AT1) receptor10,11 and are
seen at lower Ang-II concentrations than are needed for
short-term systemic hemodynamic actions.9 AT1 receptors
are also expressed in the collecting duct,12 where they regulate
epithelial Na channel activity13 and abundance.14
Regulation of renal tubule Hþ , HCO3
, and Naþ
transport by Ang-II has been investigated largely in relatively
short-term experiments with observations made within a few
minutes of Ang-II addition.1,4,7,8,15 However, there is growing
evidence that a variety of mediators of transport regulation in
the kidney, such as vasopressin16 and aldosterone,17 work by
both short-term and long-term actions. Long-term actions
are associated with increases in abundances of transporter
proteins, whereas short-term actions are associated with
regulated trafficking as well as post-translational modifica-
tions of the transporter proteins.
Approximately 70% of filtered sodium is reabsorbed in the
proximal tubule. A large portion of the apical component of
sodium, proton, and ammonium transport is mediated by
the type 3 Na7Hþ exchanger (NHE3).18 A much smaller
fraction of the total sodium absorbed enters the cell along
with phosphate ion on the type 2 sodium-phosphate
cotransporter (NaPi-2), the abundance and activity of which
changes in response to chronic acid–base disturbances.19 In
the basolateral membrane, the type 1 sodium-bicarbonate
cotransporter (NBC1) carries sodium against an electro-
chemical gradient owing to its coupling with bicarbonate
anion.20
In this study, we used antibodies to NBC1, NHE3, and
NaPi-2 to investigate whether long-term changes in Ang-II
receptor occupation are associated with changes in abun-
dance of these transporters. This is the first study that
addresses the long-term effects of changes in AT1 receptor
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occupation on the abundance of NBC1 protein and mRNA
levels. Two different experimental protocols were used to
manipulate the level of AT1 receptor occupation by Ang-II.
RESULTS
Physiological parameters
Table 1 details urine and plasma measurements in both the
candesartan and the Ang-II infusion experiments. Urinary
sodium excretion rates indicate that there were no sustained
differences between control and experimental data, indicating
that the animals had reached a steady state such that
excretion largely matched the fixed intake of solutes and
water. Potassium excretion, however, was slightly lower in
candesartan rats versus controls. In both studies, serum
aldosterone levels were low relative to the Kd of the
mineralocorticoid receptor (1.2 nM)21 and were not signifi-
cantly affected by the experimental treatments (Table 1).
Both experimental treatments significantly affected sys-
temic acid–base status. Candesartan treatment caused a
decrease in plasma bicarbonate concentration from control
values of 2671 to 2071 mM (Po0.05). Ang-II infusion had
the opposite effect on plasma bicarbonate, causing an
increase from 2570 mM in control rats to 2871 mM in
Ang-II-treated animals (Po0.05). Urinary ammonium
excretion was also lower (Po0.03) in candesartan-treated
rats (0.7370.07 mmol/day) than in controls
(0.9770.06 mmol/day) (Table 1).
Effects on NBC1 expression
Transport of bicarbonate across the basolateral plasma
membrane in the proximal tubule is mediated by NBC1.22
To test whether AT1 receptor blockade with candesartan
alters NBC1 expression, we carried out semiquantitative
immunoblotting (Figure 1). In the setting of a moderately
reduced NaCl diet (0.5 meq/200 g body weight/day NaCl),
candesartan administration resulted in a marked decrease in
renal NBC1 abundance, reducing NBC1 band density to
5979% of control. To address further the role of Ang-II in
regulation of NBC1 abundance, we infused Ang-II into rats
in which the basal levels of Ang-II was suppressed by
administration of the angiotensin-converting enzyme inhi-
bitor, lisinopril. As can be seen in Figure 1, Ang-II infusion
was associated with a significant increase in NBC1 band
density to 13077% of control. Immunoperoxidase immu-
nocytochemistry (Figure 2) confirmed that this antibody
selectively labels proximal tubules. The general distribution
of labeling was unchanged in response to candesartan
administration, suggesting that the decrease in expression is
due to a reduction in the amount of NBC1 per cell. These
images are typical of those seen in sections prepared from
three control and three candesartan-treated rats. The results
demonstrate that angiotensin II positively regulates NBC1
abundance via AT1 receptor occupation and could play a
physiological role in regulation of proximal tubule acid–base
transport.
Effects on NHE3
Total NHE3 abundance. Despite evidence for short-term
effects of Ang-II on NaCl absorption from previous studies,9
we saw no significant changes in the abundance of NHE3 in
whole kidney homogenates (WKH) (Figure 3) or cortical
homogenates (control: 100720; candesartan treated:
106716; blot not shown) in response to candesartan or
Ang-II infusion. These results suggest that Ang II does not
directly regulate total NHE3 abundance in rat kidney.
Another way of regulating NHE3 is through changes in the
abundance of NHE3 in the apical brush border, which can
occur without a change in total NHE3 through changes in the
Table 1 | Urinary excretion and serum composition
Experiments
Candesartana Ang-II
Variable Control Experimental Control Experimental
Number 6 6 6 6
Urinary excretion (mmol/day)
Na+ 0.370.1 0.470.1 2.570.1 2.570.1
K+ 1.070.1 0.870.1* 1.170.1 1.170.0
NH4
+ 0.9770.06 0.7370.07* 1.7070.10 2.0370.29
Serum
Cl (mEq/l) 10071 10672 10071 10771
HCO3
 (mmol/l) 2671 2071* 2570 2871*
Aldosterone (nmole/l) 1.070.4 0.470.2 0.170.0 0.670.2
Creatinine Cl (ml/min) 1.570.1 1.270.1 0.870.0 1.0*70.1
All values are mean7s.e.m.
*Po0.05.
aValues from the candesartan experiment (except for ammonium excretion values)
were previously published14 and are cited here for convenience.
NBC1
Whole-kidney homogenates
Vehicle Candesartan
Band density
(% vs control)
59 ± 9*
130 ± 7*
kDa:
120
120
ACEI ACEI/angiotensin II
Figure 1 | NBC1 abundance in whole kidney homogenates. Effects
of candesartan (1 mg/kg/day) blockade of the AT1 receptor
administered to rats on low-sodium diet (0.5 mEq/200 g body
weight/day) and Ang-II infusion (24 ng/min of Ang-II plus the ACE
inhibitor lisinopril) in sodium replete rats. Results are from six control
and six experimental animals in both experiments. The molecular
weight of NBC1 is marked on the left of the figure. Values on the right
were determined by densitometry expressed as percent of control
abundance. *Po0.05. Each lane of the immunoblots was loaded with
a sample from a different rat. Candesartan infusion caused a
significant decrease in NBC1 abundance, whereas Ang-II infusion
resulted in a significant increase. ACEI¼ angiotensin-converting
enzyme inhibitor.
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distribution of NHE3 among membrane subcompartments.
To test that possibility, we measured NHE3 abundance in
brush border membrane (BBM) fractions from candesartan-
treated animals as well as from Ang-II-treated animals.
Candesartan caused a small but significant decrease in BBM
NHE3, while Ang-II did not change BBM NHE3 (Figure 3).
Thus, Ang-II does not appear to cause a major change in the
amount of NHE3 in the apical BBM, although it does not
rule out changes in NHE3 within membrane subdomains
contained in the brush border (see Discussion). Indeed, as
shown in Figure 4 (NHE3 immunocytochemistry), there
was no evidence of NHE3 internalization into the endosomal
compartment in response to candesartan or Ang-II
infusion.
Effects on NaPi-2
Another transporter in the apical plasma membrane of the
proximal tubule is the sodium-phosphate cotransporter,
NaPi-2. NaPi-2 is responsible for absorption of filtered
phosphate, an important urinary buffer. As shown in Figure 5,
although infusion of Ang-II had no significant effect on
NaPi-2 abundance in WKH or BBM preparations, blockade
of the AT1 receptor with candesartan caused a decrease in
NaPi-2 abundance in WKH to 5274% of control levels. In
BBM preparations, the reduction in NaPi-2 abundance to
about 30% of control values, was even more marked
(Figure 5). The large reduction in NaPi-2 abundance was
also seen in immunostained sections (Figure 6), where the
reduction in labeling of NaPi-2 in the inner cortex in sections
from candesartan-treated rats was a consistent feature.
Effects on Na/K-ATPase
The Na/K-ATPase on the basolateral membrane maintains
low intracellular sodium concentration, providing the driving
force for a large number of secondary active transporters
including NHE3 and NaPi-2. Recently, Yingst et al.23
reported that Ang-II caused a rapid increase in Na/K-ATPase
activity in isolated rat proximal tubules. However, neither
candesartan nor Ang-II infusion significantly affected the
abundance of the a-1 subunit of Na/K-ATPase (Figure 7).
NBC1, Na/K-ATPase, NHE3, and NaPi-2 mRNA abundances
To assess the effects of candesartan infusion on the transcript
levels for the sodium transporters under investigation,
NBC1Vehicle Candesartan
Outer
cortex
Inner
cortex
Figure 2 | Immunoperoxidase labeling of NBC1 in kidney sections
(2 l paraffin-embedded sections) from vehicle- and candesartan-
treated rats. Each of the two sections shown are from different rats,
one from a control and one from a candesartan-treated rat. The
distribution of labeling of the basolateral membrane regions of
proximal tubules did not change in response to candesartan
treatment.
NHE 3 Band density
% of controlkDa
Vehicle Candesartan
83-
83-
83-
83-
ACEI ACEI/angiotensin II
Vehicle Candesartan
ACEI ACEI/angiotensin II
Whole-kidney homogenates
Brush border membrane fractions
100 ± 5
96 ± 6
70 ± 2*
97± 8
Figure 3 | NHE3 abundance in WKH and BBMs. WKH: Effects of
candesartan (1 mg/kg per day) blockade of the AT1 receptor
administered to rats on low-sodium diet (0.5 mEq/200 g body weight/
day) and Ang-II infusion (24 ng/min of Ang-II plus the ACEI inhibitor
lisinopril) in sodium replete rats. Results are from six control and six
experimental animals in both experiments. Each lane of the
immunoblots was loaded with a sample from a different rat. The
molecular weight of NHE3 is marked on the left of the figure. Values
on the right are abundance determined by densitometry expressed
as percent of control abundance. *Po0.05. Neither treatment
resulted in significant differences from control abundance. BBM
fractions: Effects of candesartan (1 mg/kg/day) blockade of the AT1
receptor administered to rats on low-sodium diet (0.5 mEq/200 g
body weight/day) and Ang-II infusion (24 ng/min of Ang-II plus the
ACE inhibitor lisinopril) in sodium replete rats. Results are from five
control and five experimental animals in each study. NHE3
abundance decreased significantly in response to candesartan
infusion (Po0.05), but there was no change in response to Ang-II
infusion. ACEI¼ angiotensin-converting enzyme inhibitor.
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real-time reverse transcriptase-polymerase chain reaction was
performed using RNA samples from WKH. No significant
differences in transcript levels were detected for any of the
four transporters (Figure 8). This includes mRNA for NBC1
and NaPi-2 for which changes in protein abundance for the
transporters were found. Candesartan treatment decreased
NBC1 protein abundance by about 40% and NaPi-2 protein
abundance by about 50% in WKH (Figures 1 and 5). These
results suggest that a lower rate of translation or an increase
in the rate of NBC1 and NaPi-2 degradation is responsible for
the decreased abundances of NBC1 and NaPi-2 protein.
DISCUSSION
The results demonstrate that Ang-II can regulate the
abundance of the basolateral bicarbonate ion transporter of
the proximal tubule, NBC1, as well as the abundance of
NaPi-2. These findings, along with those of earlier studies1–5
showing effects of Ang-II on bicarbonate, proton, and
ammonium transport, demonstrate the importance of Ang-
II in regulation of proximal tubule acid–base transport.
Decreased receptor occupation owing to candesartan
blockade and increased receptor occupation as a result
of Ang-II infusion both altered acid–base balance.
Plasma bicarbonate levels were reduced by candesartan
but were increased in response to Ang-II infusion. In
addition, candesartan treatment reduced urinary ammonium
excretion.
Conservation of plasma bicarbonate and excretion of
ammonium in the proximal tubule are key components of
the renal response to an acid load. Both these processes
depend on production of bicarbonate and ammonium ions
by glutamine metabolism in proximal tubule cells.24 In
addition, bicarbonate generated in proximal tubule cells by
carbonic anhydrase-mediated hydroxyl ion hydration must
be transported out of the cell across the basolateral
membrane to affect the systemic acid–base state. Since
NBC1 is the basolateral transporter by which most
bicarbonate is delivered to the blood, a reduction in
abundance, such as seen in these experiments in response
to candesartan treatment, would be expected to impair
bicarbonate conservation and acid–base homeostasis. Simi-
larly, the increase in plasma bicarbonate observed in response
to Ang-II infusion could have been mediated, in part, by the
observed increased NBC1 abundance. The changes in NBC1
abundance in response to decreased or increased occupation
Vehicle Candesartan
NHE3
ACEI ACEI/angiotensin II
Figure 4 | Immunoperoxidase labeling of NHE3 in kidney sections
(2 l paraffin-embedded sections) from vehicle- and candesartan-
treated rats, and from rats receiving lisinopril and vehicle versus
lisinopril plus Ang-II. Labeling shows NHE3 concentrated in the
brush border but no differences in NHE3 localization in response to
candesartan or angiotensin II treatment are apparent. The sections
are representative of three control and three experimental rats in
each study.
NaPi-2
Band density
% of control
kDa
Vehicle Candesartan
82-
82-
82-
82-
ACEI ACEI/angiotensin II
Vehicle Candesartan
ACEI ACEI/angiotensin II
Whole-kidney homogenates
Brush border membrane fractions
52± 4*
80 ± 7
32± 4*
78± 13
Figure 5 | NaPi-2 abundance in WKH and BBMs. WKH: Effects of
candesartan (1 mg/kg per day) blockade of the AT1 receptor
administered to rats on low-sodium diet (0.5 mEq/200 g body weight/
day) and Ang-II infusion (24 ng/min of Ang-II plus the ACE inhibitor
lisinopril) in sodium replete rats. Results are from six control and six
experimental animals in both experiments. Each lane of the
immunoblots was loaded with a sample from a different rat. The
molecular weight of NaPi-2 is marked on the left of the figure. Values
on the right are abundances determined by densitometry expressed
as percent of control abundance. *Po0.05. Candesartan treatment
caused a significant decrease compared to control abundance, but
Ang-II infusion had no effect. BBM fractions: Effects of candesartan
blockade of the AT1 receptor (1 mg/kg/day) administered to rats on
low-sodium diet (0.5 mEq/200 g body weight/day) and Ang-II
infusion (24 ng/min of Ang-II plus the ACE inhibitor lisinopril) in
sodium replete rats. Results are from five control and five
experimental animals. NaPi-2 abundance decreased significantly in
response to candesartan infusion but there were no significant
effects of Ang-II. ACEI¼ angiotensin-converting enzyme inhibitor.
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of the AT1 receptor by Ang-II seen in this study fit well with
previous observations. Earlier work has shown that both
sodium and bicarbonate absorption are stimulated by Ang-
II9,15,25 and that the response is mediated by Ang-II binding
the AT1 receptor.10,11
The transporter whose abundance was most dramatically
affected by candesartan treatment was NaPi-2. The decreases
observed in WKH and BBM fractions could be in response to
the apparent metabolic acidosis suggested by the low plasma
bicarbonate ion levels seen in candesartan-treated rats.
Previous studies in this laboratory demonstrated that NaPi-
2 abundance decreases in response to acid loading.19 In
contrast to blockade of the AT1 receptor, Ang-II infusion did
not significantly affect NaPi-2 abundance in either WKH or
BBM fractions. This supports the hypothesis that the
decrease in NaPi-2 abundance seen in response to cande-
sartan was due to the apparent metabolic acidosis. Down-
regulation of NaPi-2 abundance would be expected to
contribute to increased urinary phosphate excretion and
thus to increased net acid excretion. In contrast, it is unlikely
that the observed decrease in NBC1 abundance in response to
candesartan was due to acidosis since Kwon et al.26 found no
change in NBC1 abundance in rats subjected to chronic
metabolic acidosis.
In our studies, urinary ammonium excretion was reduced
by candesartan to about 75% of control values due perhaps
to the observed modest reduction of NHE3 abundance in
BBM. Another, perhaps more likely, possibility is that
impaired ammonium excretion in response to candesartan
was a result of reduced ammonium production in proximal
tubule cells. Nagami5,27 demonstrated that ammonia produc-
tion, as well as secretion, in the S2 segment of mouse
NaPi-2Vehicle Candesartan
Outer
cortex
Inner
cortex
Outer
medulla
Figure 6 | Immunoperoxidase labeling of NaPi-2 in kidney
sections (2 l paraffin-embedded sections) from control and
candesartan-treated (1 mg/kg/day) rats. Labeling shows heavy
labeling of NaPi-2 in the inner cortex in sections from control rats.
Labeling is decreased markedly in response to candesartan infusion.
The sections are representative of three control and three
candesartan-treated rats.
Band density
% of controlkDa Vehicle Candesartan
100-
100-
ACEI ACEI/angiotensin II
Whole-kidney homogenates
83± 5
90 ±19
Na/K-ATPase  -1 subunit
Figure 7 | Na/K-ATPase, a-1 subunit abundance in whole kidney
homogenates. Effects of candesartan blockade of the AT1 receptor
(1 mg/kg/day) administered to rats on low-sodium diet (0.5 mEq/
200 g body weight/day) and Ang-II infusion (24 ng/min of Ang-II plus
the ACE inhibitor lisinopril) in sodium replete rats. Results are from six
control and six experimental animals in both experiments. The
molecular weight of the a-1 subunit of Na/K-ATPase is marked on the
left of the figure. Values on the right are abundances determined by
densitometry expressed as percent of control abundance. Each lane
of the immunoblots was loaded with a sample from a different rat.
Neither treatment caused a significant change in abundance.
ACEI¼ angiotensin-converting enzyme inhibitor.
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Figure 8 | Effect of AT1 blockade on Naþ transporter transcript
levels. Transcript levels for the four sodium transporters studies in
these experiments were determined by reverse transcriptase-
polymerase chain reaction. Solid bars represent means of determi-
nations from six rats in each group and the small vertical bars show
s.e.m. values. Candesartan blockade of the AT1 receptor had no
significant effect on mRNA amounts.
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proximal tubules is stimulated by Ang-II and that the effects
are enhanced by acid loading.
Long-term candesartan treatment or angiotensin infusion
had no effect on NHE3 abundance in kidney homogenates.
Furthermore, there was little (with candesartan treatment) or
no (with Ang-II infusion) change in BBM NHE3 with
changes in AT1 receptor occupancy, a finding further
supported by a lack of immunocytochemical evidence for
NHE3 redistribution in the proximal tubule cell. This
seemingly contrasts with the findings of other investigators,
showing that physiological conditions that increase renal
cortex NHE3 activity, such as chronic metabolic acidosis,28,29
cause no change in NHE3 abundance in homogenates of the
cortex19 but can result in increased abundance of NHE3 in
brush border.30,31 However, the findings of Biemesderfer32
and Yang et al.33 appear compatible with the view that NHE3
is regulated in part through redistribution between different
subregions of the apical plasma membrane, viz. the microvilli
and the inter-microvillar clefts. Neither of our measurements
(immunoblotting of BBM fractions or immunocytochemis-
try) would necessarily be expected to reveal such changes.
Thus, we cannot rule out the possibility that the changes in
AT1 receptor occupation in our studies were associated with
such a microvillar to inter-microvillar transition. In addition
to changes in abundance in the BBM, it is also possible that
Ang-II regulates NHE3-mediated transport though post-
translational modifications, induced protein–protein interac-
tions, or altered ion gradients, mechanisms that would not be
reflected in our immunoblots.
Candesartan treatment did not produce significant
changes in the levels of mRNA for NBC1, NaPi-2, NHE3,
or Na/K-ATPase. It is not unusual to see changes in
transporter protein abundance without changes in message
levels. Protein abundances are affected by their biological
half-life as well as the half-life of the mRNA that codes
for them.
CONCLUSION
Immunoblots and immunocytochemistry show that decreas-
ing AT1 receptor occupation by candesartan blockade
decreased abundance of NBC1, the principal bicarbonate
transporter of the basolateral membrane in proximal tubules,
whereas increased receptor occupation owing to Ang-II
infusion increased NBC1 abundance. Changes in the activity
of NBC1 would be expected to significantly affect systemic
acid–base balance and in these experiments candesartan
treatment of rats produced a 23% decrease in serum
bicarbonate. Candesartan blockade of Ang-II binding to the
AT1 receptor also caused significant decreases in the
abundance of NaPi-2, a transporter in the apical membrane
of proximal tubule cells that contributes to net acid excretion.
These findings, interpreted in light of earlier studies, suggest
that proximal tubule regulation of bicarbonate absorption by
Ang-II is an important component of systemic acid–base
homeostasis.
MATERIALS AND METHODS
Experimental animals and treatment protocols
Candesartan blockade of the AT1 receptor for Ang-II. To
assess the effects of blockade of the AT1 receptor on transporter
abundance, we infused candesartan into male Sprague–Dawley rats
(224–250 g body weight) housed in metabolic cages under controlled
temperature and light conditions (12 h day and night cycles).
Sodium and water intake were controlled by ration feeding. Rats
were given daily pre-weighed portions of an agar gel diet to provide
(per 200 g body weight) 25 ml water and 15 g of nominally NaCl-free
purified rodent chow (product #53140000, Zeigler Bros, Garners,
PA, USA) with addition of 0.5 mEq NaCl/day.34 This is a low level of
NaCl intake, approximately 1/4th that of standard rat chow. Urine
samples, collected daily, were preserved with thymol and evapora-
tion was prevented with a layer of mineral oil. After a 4-day
equilibration period on the low-sodium diet, rats were anesthetized
with methoxyflurane (Metophane, Schering-Plough Animal Health
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Figure 9 | Characterization of protein abundance from BBM
preparations prepared by MgCl2 precipitation from rats main-
tained on the low-sodium diet (0.5 mEq/200 g body weight/day).
Molecular weights are marked for the predominant form of each
transporter. Densitometric analysis showed that NHE3 was enriched
to approximately 633% of the WKH amount. The apical membrane
markers g-glutamyltransferase and NaPi-2 were enriched about
10-fold and megalin was enriched about 3-fold, whereas the vesicle-
associated membrane protein (VAMP2) concentration was decreased
to about 10% of the WKH amount. NBC1 was decreased to about
57% of WKH.
Kidney International (2006) 70, 660–668 665
S Turban et al.: Angiotensin II regulation of NBC1 o r i g i n a l a r t i c l e
Corp., Union, NJ, USA) for subcutaneous implantation of osmotic
minipumps containing candesartan (AstraZeneca, Mo¨lndal, Sweden;
a kind gift from Dr Peter Morsing). Candesartan was solubilized in
0.02 M Na2CO3 in physiological saline. Experimental rats were given
candesartan at a dose of 1 mg/kg/day, whereas control rats received
only the saline/Na2CO3 vehicle.
The choice of a daily dietary sodium intake of 0.5 mEq/200 g
body weight per day Na was based on preliminary studies which
showed that lower intake of NaCl compromised renal function when
combined with candesartan treatment. Specifically, in preliminary
experiments, rats treated with candesartan and fed diets containing
0.03 or 0.3 mEq NaCl/200 g body weight showed evidence of
decreased glomerular filtration rate in comparison to controls eating
the low-salt diets but not treated with candesartan. At those lower
salt levels, serum creatinine values were more than twice as high as
control values and creatinine clearance was approximately 50% of
control. In addition, immunoblots showed that the abundance of
both NHE3 and Na/K-ATPase in cortical homogenates decreased
significantly in the candesartan-treated groups (data not shown). At
a dietary level of 0.5 mEq NaCl/200 g body weight, candesartan
treatment did not significantly affect creatinine clearance or serum
creatinine levels (Table 1).
After 2 days, animals were killed and trunk blood was collected.
For semiquantitative immunoblotting, kidneys were rapidly re-
moved and processed. For immunocytochemistry, animals were
anesthetized as above and kidneys were perfusion-fixed in situ.
Perfusion pressure was controlled and did not exceed 100 mm Hg.
Ang-II infusion
To assess the effects of increased occupation of the AT1 receptor by
Ang-II on transporter abundance, we infused Ang-II into male
Sprague–Dawley rats (224–250 g body weight) housed in metabolic
cages and ration-fed the same amounts of water and food as given in
the candesartan-infusion experiments, except that in these experi-
ments 2.0 mEq NaCl/200 g body weight was added to the food
ration. This is a standard level of salt intake for rats. Urine
samples were collected as above. All rats in this experiment
received long-term infusions of the angiotensin-converting
enzyme inhibitor, lisinopril (AstraZenica; a kind gift from Dr Peter
Morsing), and either Ang-II (Calbiochem, LaJolla, CA, USA) or the
vehicle for Ang-II, described as follows. After 1 day of acclimation in
metabolic cages, rats were anesthetized with isoflurane (Abbott
Laboratories, North Chicago, IL, USA) and osmotic minipumps
(Alzet, Cupertino, CA, USA) were implanted subcutaneously. The
lisinopril (3 mg/kg/day) was given to all rats to minimize the
endogenous production of Ang-II. Separate minipumps delivered
24 ng/min of Ang-II dissolved in 0.001 N acetic acid to experimental
animals or vehicle (0.001 N acetic acid) alone to control rats.
This was a mid-dose level from a previous study in our laboratory14
and was within the range that resulted in increases in a-epithelial Na
channel protein abundance. The dose used was designed to
be a so-called ‘non-pressor’ dose, meaning that the dose is low
relative to that needed for an immediate increase in blood
pressure. After 3 days of treatment, rats were killed by
decapitation, and kidneys were rapidly removed and prepared
for semiquantitative immunoblotting. For immunocytochemistry,
animals were anesthetized as above and kidneys were perfusion-
fixed in situ.
All experiments were carried out in accordance with the Guide
for Care and Use of Laboratory Animals and with the approval of the
Institutional Animal Care and Use Committee.
Urine and serum chemistry
Measurements of urine and serum chemistry were done using an
autoanalyzer (Monarch 2000 autoanalyzer, Instrumentation Labora-
tories, Lexington, MA, USA). Urine ammonium was determined
using an enzymatic method (Sigma Diagnostics Procedure No. 170-
UV). Serum aldosterone concentration (Coat-A-Count Aldosterone,
Diagnostic Products Corp, Los Angeles, CA, USA) was measured by
radioimmunoassay of serum.
Semiquantitative immunoblotting
The methods used have been described in detail elsewhere.35,36 In all
experiments, Coomassie-stained ‘loading-control’ gels were pre-
pared to ensure equality of loading. To do this, sodium dodecyl
sulfate -solubilized (solubilized with Laemmli sample buffer)
samples of each homogenate or isolated membrane preparation
were run on 12% polyacrylamide/sodium dodecyl sulfate gels.
Selected bands on the loading gels were quantified by densitometry.
Loading of gels for immunoblotting was adjusted according to the
densitometry results to assure equal loading within 5% of the mean.
Antibodies
The antibodies used for immunoblotting and immunocytochem-
istry have been characterized by Kim et al.19,35 (NHE3 and NaPi-2)
and Schmitt et al.37 (NBC1). A mouse monoclonal antibody against
the a-subunit of Naþ /Kþ -ATPase was obtained from Upstate
Biotechnology (Lake Placid, NY, USA).
Membrane fraction preparation
Kidneys of rats were rapidly removed and chilled in ice-cold PBS.
Aliquots of whole kidney homogenate (WKH) from each rat were
used to prepare membrane fractions by the Mg-precipitation
method as described by Biber et al.38 and Fernandez-Llama et al.39
The pellet resulting from the final centrifugation, consisting largely
of apical plasma membranes of renal tubule epithelial cells, was re-
suspended in isolation solution and solubilized in Laemmli sample
buffer for subsequent immunoblotting.
Composition of the final pellet was determined by comparing
membrane fraction isolate with WKH from the same rat. Previous
characterization by Biber et al.38 showed that the final pellet was
enriched in marker enzymes of the brush border (alkaline
phosphatase and aminopeptidase M). Marker enzymes for mito-
chondria, endoplasmic reticulum, and secretory vesicles were absent.
We characterized our membrane fractions by immunoblott-
ing (Figure 9) using antibodies to the brush border enzyme
g-glutamyltransferase (a kind gift of Dr Rebecca Hughey, University
of Pittsburgh),40 vesicle-associated membrane protein,34 NaPi-2,19
and NBC1 (Chemicon International Inc., Temecula, CA, USA).
Immunoblots showed appropriate enrichment of BBM marker
proteins. Specifically, the apical membrane markers g-glutamyl-
transferase and NaPi-2 were enriched about 10-fold and megalin was
enriched nearly 3-fold. NHE3 was enriched about 6-fold, whereas
the vesicle-associated membrane protein abundance was decreased
to about 10% of the WKH amount. The basolateral membrane
protein NBC1 was de-enriched to about 57% of WKH levels.
Immunocytochemistry
Kidneys were perfusion-fixed with a paraformaldehyde-based
fixative and 2 m paraffin-embedded sections were prepared as
described by Nielsen et al.41 Sections were labeled using the
immunoperoxidase method of Hager et al.42
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Real-time reverse transcriptase-polymerase chain reaction
Quantitative, real-time reverse transcription-polymerase chain
reaction (ABI Prism 7900HT) was used to measure relative mRNA
abundances in kidneys of vehicle-treated and candesartan-treated
rats as previously described.43 The primer sequences used are given
as supplementary materials in Brooks et al.43 Relative quantification
of gene expression was achieved using the comparative CT method.
Validation experiments were performed to show that amplification
efficiencies were equal between control and experimental groups.44
Specificity of the amplified products was determined using melting
curve analysis and by product sequencing.
Statistical analysis
Values for experimental rats were compared with controls using an
unpaired t-test when s.ds. were the same or by Welch’s t-test when
s.ds. were significantly different (INSTAT; Graphpad Software, San
Diego, CA, USA). Relative quantification of the band densities from
immunoblots was carried out by densitometry using a laser
densitometer (Molecular Dynamics, San Jose, CA, USA) and
ImageQuaNT software (Molecular Dynamics). To facilitate compar-
isons, we normalized the densitometry values such that the mean for
the control group is defined as 100%. Po0.05 was considered
statistically significant. All numerical values are reported as
mean7s.e.m.
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